What is the dosage of Enhertu?

Enhertu is available in 1 dosages, including 100 mg Injection

What does Enhertu treat?

Enhertu treats Breast Neoplasms and Gastrointestinal Neoplasms

What is Enhertu made of?

Enhertu contains trastuzumab which is a HER2/neu Receptor Antagonist

How is Enhertu administered?

Enhertu is administered as a Injectable

What is Enhertu mechanism of action?

Enhertu mechanism of action is HER2/Neu/cerbB2 Antagonists

Dosage & Administration Efficacy safety testing Drug label Prior authorization Financial assistance

Patient education

Enhertu

(trastuzumab)

fam-trastuzumab deruxtecan-nxki 100 MG Injection [Enhertu]

BLACK BOX WARNING

Dosage & administration

* Do not substitute ENHERTU for or with trastuzumab or ado-trastuzumab emtansine.
* For intravenous infusion only. Do not administer as an intravenous push or bolus. DO NOT use Sodium Chloride Injection, USP.
* Premedicate for prevention of chemotherapy-induced nausea and vomiting.
* The recommended dosage of ENHERTU for breast cancer is 5.4 mg/kg given as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.
* The recommended dosage of ENHERTU for lung cancer is 5.4 mg/kg given as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.
* The recommended dosage of ENHERTU for gastric cancer is 6.4 mg/kg given as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.
* Management of adverse reactions (ILD, neutropenia, thrombocytopenia, or left ventricular dysfunction) may require temporary interruption, dose reduction, or discontinuation of ENHERTU.

eficacy, safety & testing

Enhertu clinical details

Mechanism of Action: HER2 Low mBC

Dosing and Administration: HER2 Low mBC

Warnings and Precautions: HER2 Low mBC

Clinical Trials: DESTINY - Breast04 (HER2 Low mBC)

Efficacy (HR+/HER): HER2 Low mBC

Efficacy (HR+/and HR-/HER2): HER2 Low mBC

Safety Profile: HER2 Low mBC

Managing Potential Treatment Risks - Interstitial Lung Disease (ILD) and Pneumonitis: HER2 Low mBC

Managing Potential Treatment Risks - Neutropenia: HER2 Low mBC

Managing Potential Treatment Risks - Left Ventricular Dysfunction: HER2 Low mBC

Managing Potential Treatment Risks - Thrombocytopenia: HER2 Low mBC: HER2 Low mBC

Managing Potential Treatment Risks - Other Select Adverse Reactions: HER2 Low mBC

Mechanism of Action: HER2+ mBC

Dosing and Administration: HER2+ mBC

Warnings and Precautions: HER2+ mBC

Clinical Trial: DESTINY Breast03 (HER2+ mBC)

Efficacy (Progression-Free Survival): HER2+ mBC

Efficacy (Objective Response Rate): HER2+ mBC

Efficacy (Tumor Response): HER2+ mBC

Efficacy (Overall Survival): HER2+ mBC

Safety Profile: HER2+ mBC

DESTINY-Breast01 Clinical Trial Data: HER2+ mBC

Managing Potential Treatment Risks - Interstitial Lung Disease (ILD) and Pneumonitis: HER2+ mBC

Managing Potential Treatment Risks - Neutropenia: HER2+ mBC

Managing Potential Treatment Risks - Left Ventricular Dysfunction: HER2+ mBC

Managing Potential Treatment Risks - Thrombocytopenia: HER2+ mBC

Managing Potential Treatment Risks - Other Select Adverse Reactions: HER2+ mBC

Mechanism of Action: HER2+ aGC

Dosing and Administration: HER2+ aGC

Warnings and Precautions: HER2+ aGC

Clinical Trial: DESTINY-Gastric01 (HER2+aGC)

Efficacy (Median Overall Survival): HER2+ aGC

Efficacy (Progression-Free Survival): HER2+ aGC

Efficacy (Objective Response Rate): HER2+ aGC

Efficacy (Tumor Response): HER2+ aGC

Safety Profile: HER2 aGC

DESTINY-Gastric02 Clinical Data: HER2+ aGC

Managing Potential Treatment Risks - Neutropenia: HER2+ aGC

Managing Potential Treatment Risks - Left Ventricular Dysfunction: HER2+ aGC

Managing Potential Treatment Risks -Thrombocytopenia: HER2+ aGC

Managing Potential Treatment Risks - Interstitial Lung Disease (ILD) and Pneumonitis: HER2+ aGC

Testing: HER2-mutant mNSCLC

Mechanism of Action (MOA): HER2-mutant mNSCLC

Warning & Precautions: HER2-mutant mNSCLC

Dosing & Administration: HER2-mutant mNSCLC

Clinical Trial: DESTINY-Lung02 (HER2-mutant mNSCLC)

Efficacy & Safety Profile: HER2-mutant mNSCLC

drug label

Enhertu prescribing information

Have more Enhertu questions?

Submit MSL Request

Learn More

Need to report an Enhertu issue?

ONLINE FORMReport adverse event

Learn More

prior authorization

Enhertu Prior authorization resources

Complete Letter of Medical Necessity

NOT PROVIDED BY BRANDCoverage Authorization Request

Coverage Authorization Appeals

Enhertu PA Checklist

Learn More

Benefits investigation

Enhertu4u Enrollment Form

Enhertu4u Enrollment Form - Spanish

Learn More

Reimbursement help (FRM)

NOT PROVIDED BY BRANDReimbursement help (FRM) resources

Learn More

financial assistance

Enhertu Financial assistance options

Co-pay savings program

commercial only

Enhertu4u Enrollment Form

Enhertu4u Enrollment Form - Spanish

Enroll in Patient Savings Program

Enroll in Patient Savings Program - HCP Office Online Portal

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Bridge program

commercial only

Learn More

Overview

Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)

Patient benefit

100% free (outside of insurance)

Patient eligibility

HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries

How to sign up

Typically HCP assisted enrollment (via form)

Foundation programs

under insured

no insurance

goverment insurance

65+

Patient Assistance Program Enrollment Form - English

Patient Assistance Program Enrollment Form - Spanish

Independent Financial Support Programs

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement

patient education

Enhertu Patient education

Getting started on Enhertu

NOT PROVIDED BY BRANDInstructions For Use: HER2-mutant mNSCLC

NOT PROVIDED BY BRANDInstructions For Use: HER2+ aGC

NOT PROVIDED BY BRANDInstructions For Use: HER2+ mBC

NOT PROVIDED BY BRANDInstructions For Use: HER2 Low mBC